FluoSphera's revolutionary drug discovery project secures CHF 1.1 million grant from Innosuisse
25.01.2024
FluoSphera, a biotechnology company, has proudly announced the receipt of a CHF 1.1 million grant from Innosuisse, the Swiss Innovation Agency. Teaming up with the renowned EPFL and the University of Geneva, FluoSphera's disruptive innovation project aims to revolutionize in-vitro solutions for drug discovery. The collaboration aims to develop innovative assays for improved drug efficacy and safety prediction.
 FluoSphera Co-founders: CEO Gregory Segala and COO Clelia Bourgoint
|
 |
FluoSphera is set to start a two-year research project with a budget of CHF 2.3 million, focusing on overcoming challenges in predicting drug toxicity effects in humans. The FluoSphera platform, unlike traditional translational methods, assesses drug safety and efficacy using human 3D models and systemic drug exposure. The research aims to generate precise, multiplexed data for more accurate human response prediction compared to conventional methods. By partnering with the team of Professor Gerardo Turcatti, Director of Biomolecular Screening Platform at EPFL in Lausanne, and with the laboratory of Professor Aurélien Roux, Professor at the University of Geneva and Scientific Director of ACCESS-Geneva, the project will calibrate assays for high-content screening and validate services for market entry.
FluoSphera aims to revolutionize drug discovery, reducing risks and timelines, and ultimately increasing the availability of safe and effective medicines for patients in need through direct sales, licensing, partnerships, and collaborations within the pharmaceutical industry.
“We are honored to receive this support from Innosuisse and thank the Innovation Council for supporting our project. We also thank Dr. Med. Marco Rüedi, our lead coach in the frame of our Innosuisse Core Coaching program, for his guidance in transferring our disruptive innovation to the market” said Clelia Bourgoint, COO and Co-Founder of FluoSphera.
FluoSphera won the second stage of Venture Kick in 2022. "Venture Kick provided FluoSphera a bootstrapping support that allowed us to join the World's biggest biotech accelerator, IndieBio New York, to raise our pre-seed round, and to reach a level of technology and business maturity to obtain this substantial support of our innovation project by Innosuisse," commented Gregory Segala, CEO of FluoSphera.
FluoSphera aims to revolutionize drug discovery, reducing risks and timelines, and ultimately increasing the availability of safe and effective medicines for patients in need through direct sales, licensing, partnerships, and collaborations within the pharmaceutical industry.
“We are honored to receive this support from Innosuisse and thank the Innovation Council for supporting our project. We also thank Dr. Med. Marco Rüedi, our lead coach in the frame of our Innosuisse Core Coaching program, for his guidance in transferring our disruptive innovation to the market” said Clelia Bourgoint, COO and Co-Founder of FluoSphera.
FluoSphera won the second stage of Venture Kick in 2022. "Venture Kick provided FluoSphera a bootstrapping support that allowed us to join the World's biggest biotech accelerator, IndieBio New York, to raise our pre-seed round, and to reach a level of technology and business maturity to obtain this substantial support of our innovation project by Innosuisse," commented Gregory Segala, CEO of FluoSphera.